German’s Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has opened its scientific office in Nairobi, Kenya.
The new office will serve as the company’s headquarters for the Sub-Saharan Africa region and is poised to expand the company’s global presence in the area.
“For over two decades, Boehringer Ingelheim has been committed to improving human and animal health in Africa,” Mohammed Tawil, Regional Managing Director and Head of Human Pharma at Boehringer Ingelheim India, the Middle East, Turkey, and Africa (‘IMETA’) said.
“Our presence here will enable us to better understand the needs of the local communities and work in partnership with healthcare providers and regulators to bring healthcare solutions in areas of unmet medical need. We are dedicated to making a positive impact on the health and well-being of patients, animals and communities at large, and we believe that our investment in Kenya is an important step towards achieving this goal.”
In Kenya, Boehringer Ingelheim has been active with its SD4G plans. ‘Access to Healthcare’ is one of the key initiatives launched in Kenya in August 2022.
The initiative has offered more than 1000 patients comprehensive services, including medical screening and follow-ups for people living with Chronic Obstructive Pulmonary Disease (COPD).
In 2018, the company also launched the LastMile initiative in Kenya. This integrated, solutions-driven programme seeks to address crucial animal health challenges by creating consistent availability of animal medical resources in hard-to-reach areas.
Boehringer Ingelheim Ranks 12 in 2021 Access-To-Medicine Index
